Related Experiment Video
Updated: May 15, 2026

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence
Published on: January 7, 2019
POD-1 binding to the E-box sequence inhibits SF-1 and StAR expression in human adrenocortical tumor cells
Monica Malheiros França1, Bruno Ferraz-de-Souza, Mariza Gerdulo Santos
1Department of Anatomy, Institute of Biomedical Sciences, University of São Paulo, São Paulo 05508-900, SP, Brazil.
Abstract:
Pod-1/Tcf21 is expressed at epithelial-mesenchymal interaction sites during development of many organs. Different approaches have demonstrated that Pod-1 transcriptionally inhibits Sf-1/NR5A1 during gonadal development. Disruption of Sf-1 can lead to disorders of adrenal development, while increased dosage of SF-1 has been related to increased adrenal cell proliferation and tumorigenesis. In this study, we analyzed whether POD-1 overexpression inhibits the endogenous Sf-1 expression in human and mouse adrenocortical tumor cells. Cells were transiently transfected with luciferase reporter gene under the control of Sf-1 promoter and with an expression vector encoding Pod-1. Pod-1 construct inhibited the transcription of the Sf1/Luc reporter gene in a dose-dependent manner in mouse Y-1 adrenocortical carcinoma (ACC) cells, and inhibited endogenous SF-1 expression in the human H295R and ACC-T36 adrenocortical carcinoma cells. These results were validated by chromatin immunoprecipitation assay with POD-1-transfected H295R cells using primers specific to E-box sequence in SF-1 promoter region, indicating that POD-1 binds to the SF-1 E-box promoter. Moreover, POD-1 over-expression resulted in a decrease in expression of the SF-1 target gene, StAR (Steroidogenic Acute Regulatory Protein). Lastly, while the induced expression of POD-1 did not affect the cell viability of H295R/POD-1 or ACC-T36/POD-1 cells, the most significantly enriched KEGG pathways for genes negatively correlated to POD-1/TCF21 in 33 human ACCs were those associated with cell cycle genes.
Insights
Pod-1/Tcf21 inhibits Steroidogenic Factor-1 (SF-1) expression in adrenocortical tumor cells, impacting SF-1 target genes like StAR. Overexpression of POD-1 did not affect cell viability but correlated with cell cycle pathways in human ACCs.
Area of Science:
- Endocrinology
- Molecular Biology
- Oncology
Background:
- Pod-1/Tcf21 is involved in organ development and known to inhibit Steroidogenic Factor-1 (SF-1) during gonadal development.
- SF-1 disruption causes adrenal disorders, while its overexpression is linked to adrenal cell proliferation and tumorigenesis.
Purpose of the Study:
- To investigate if POD-1 overexpression inhibits endogenous SF-1 expression in human and mouse adrenocortical tumor cells.
- To determine the effect of POD-1 on SF-1 target genes and cell cycle pathways in adrenocortical carcinoma (ACC).
Main Methods:
- Transient transfection of adrenocortical cells (mouse Y-1, human H295R, ACC-T36) with POD-1 expression vectors and SF-1 promoter-luciferase reporter.
- Chromatin immunoprecipitation (ChIP) assay to confirm POD-1 binding to the SF-1 promoter.
- Analysis of SF-1 target gene StAR expression and correlation of POD-1/TCF21 with KEGG pathways in human ACCs.
Main Results:
- POD-1 inhibited SF-1 promoter-driven luciferase reporter gene transcription in a dose-dependent manner.
- POD-1 overexpression suppressed endogenous SF-1 expression in human and mouse ACC cells.
- ChIP assay confirmed POD-1 binding to the E-box sequence in the SF-1 promoter.
- POD-1 overexpression decreased the expression of the SF-1 target gene, StAR.
- Induced POD-1 expression did not affect cell viability but was negatively correlated with cell cycle genes in human ACCs.
Conclusions:
- POD-1/Tcf21 acts as a transcriptional repressor of SF-1 in adrenocortical tumor cells.
- POD-1 influences SF-1-mediated pathways, including StAR expression, and is associated with cell cycle regulation in adrenocortical tumors.
Related Concept Videos
Abnormal Proliferation
Eukaryotic Transcription Inhibitors
Eukaryotic transcription inhibitors usually contain two distinct domains, a DNA...
Cell Specific Gene Expression
NF-kB-dependent Signaling Pathway
NF-κB-dependent Signaling Mechanism
The heterodimer of NF-κB...
Cushing Syndrome II: Pathophysiology
NF-κB-dependent Signaling Pathway
NF-κB-dependent Signaling Mechanism
The heterodimer of NF-κB...
